Agilent Technologies A Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Agilent CrossLab | $759M+0.1% | $758M+0.4% | $755M+1.5% | $744M+4.3% | $713M+2.4% | |
| Applied Markets | $344M-4.7% | $361M+2.8% | $351M+8.3% | $324M+7.6% | $301M-10.9% | |
| Life Sciences and Diagnostics Markets | $732M+7.8% | $679M-10.1% | $755M+12.7% | $670M+2.4% | $654M+1.1% | |
| Cost of revenue by Business | ||||||
| Agilent CrossLab | $338M-0.6% | $340M— | —— | —— | $317M+3.6% | |
| Applied Markets | $152M-3.2% | $157M— | —— | —— | $140M-6.7% | |
| Life Sciences and Diagnostics Markets | $337M+0.3% | $336M— | —— | —— | $309M+1.3% | |
| Income from operations by Business | ||||||
| Agilent CrossLab | $242M+0.8% | $240M-2.4% | $246M-0.8% | $248M+7.4% | $231M+4.5% | |
| Applied Markets | $80M-14.0% | $93M+6.9% | $87M+22.5% | $71M+20.3% | $59M-29.8% | |
| Life Sciences and Diagnostics Markets | $161M+47.7% | $109M-36.6% | $172M+45.8% | $118M-8.5% | $129M+10.3% | |
| Selling, General and Administrative Expense by Business | ||||||
| Agilent CrossLab | $151M+0.7% | $150M— | —— | —— | $138M-3.5% | |
| Applied Markets | $88M+1.1% | $87M— | —— | —— | $79M-2.5% | |
| Life Sciences and Diagnostics Markets | $170M+0.6% | $169M— | —— | —— | $157M-3.1% | |
| Research and Development Expense by Business | ||||||
| Agilent CrossLab | $28M0.0% | $28M— | —— | —— | $27M+3.8% | |
| Applied Markets | $24M0.0% | $24M— | —— | —— | $23M0.0% | |
| Life Sciences and Diagnostics Markets | $64M-1.5% | $65M— | —— | —— | $59M-6.3% | |
| Foreign currency translation impact by Business | ||||||
| Agilent CrossLab | $1M-66.7% | $3M— | —— | $1M— | —— | |
| Share-based compensation expense by Business | ||||||
| Agilent CrossLab | $12M-25.0% | $16M— | —— | —— | $11M-31.3% | |
| Applied Markets | $6M-14.3% | $7M— | —— | —— | $5M-37.5% | |
| Life Sciences and Diagnostics Markets | $11M-21.4% | $14M— | —— | —— | $9M-40.0% | |
| Depreciation by Business | ||||||
| Agilent CrossLab | $14M0.0% | $14M— | —— | —— | $14M0.0% | |
| Applied Markets | $7M+16.7% | $6M— | —— | —— | $6M0.0% | |
| Life Sciences and Diagnostics Markets | $26M0.0% | $26M— | —— | —— | $24M+4.3% | |
| Goodwill by Business | ||||||
| Agilent CrossLab | $1.17B+0.1% | $1.17B+0.3% | $1.17B0.0% | $1.17B+0.1% | $1.17B+0.3% | |
| Applied Markets | $315M-0.3% | $316M+2.3% | $309M0.0% | $309M+0.3% | $308M+1.3% | |
| Life Sciences and Diagnostics Markets | $3B0.0% | $3B0.0% | $3B-0.1% | $3B0.0% | $3B+1.3% | |
| Net revenue by Product | ||||||
| Instrumentation | $618M-6.1% | $658M+0.8% | $653M+9.0% | $599M+8.9% | $550M-12.0% | |
| Non-Instrumentation and Other | $1.22B+6.8% | $1.14B-5.6% | $1.21B+6.1% | $1.14B+1.9% | $1.12B+5.9% | |
| Services and Other | $530M+1.0% | $525M-1.5% | $533M+4.9% | $508M+5.4% | $482M+0.2% | |
| Net revenue by Geography | ||||||
| Americas | $764M+12.7% | $678M-12.6% | $776M+13.6% | $683M+0.7% | $678M+1.3% | |
| Asia Pacific | $553M-8.1% | $602M+7.7% | $559M-0.7% | $563M+2.7% | $548M-0.2% | |
| Europe | $518M0.0% | $518M-1.5% | $526M+6.9% | $492M+11.3% | $442M-4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Agilent Technologies break its business down?
- Agilent Technologies (A) reports net revenue by business across 3 parts — Agilent CrossLab, Applied Markets and Life Sciences and Diagnostics Markets. Each is extracted from the segment footnotes and tracked over time.
- Where does Agilent Technologies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Agilent Technologies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
